The invention is about a high-efficient and low-cost system to prepare a specific type of human T cells (human alloantigen-specific CD8hi Tregs) at a large scale and the novel therapy against immune disorder diseases such as transplantation-related diseases, autoimmune diseases, and allergy without supressing general immunity.
Current strategy to treat transplantation-related diseases, autoimmune diseases, and allergy relied on the general suppression of immune system led to severe side effects such as opportunistic infections and tumor relapse. For transplantation, less than 5% of patients can undergo transplantation due to the failure of human leukocyte antigens (HLA)-match for bone marrow and transplantation. Treg-based therapy might address the problem.
Founded in 1911, The University of Hong Kong (HKU) is the first and oldest institution of higher education in Hong Kong. For over a century, the University has dedicated itself to creating knowledge, providing education, and serving society. Today, HKU has an established worldwide reputation for being a research-led comprehensive University with ten Faculties and a strong commitment to intellectual freedom, liberty and diversity. HKU has a proud record of academic recognition in researches through honours and awards received from both local and international bodies.